MAPK8 and chronic obstructive pulmonary disease: We investigated the effects of the LABAs formoterol and salmeterol and the corticosteroid fluticasone-propionate (all approved for COPD) and of the MAPK inhibitors BIRB796 (inhibitor of p38MAPKα, -γ, -δ isoforms), SB203580 (p38MAPKα and -β inhibitor), PD098059 (inhibitor of ERK activation), and SP600125 (inhibitor of JNK).